The effects of Peg-IFN-a2b immunotherapy on gut tissue HIV-1 RNA remain unknown. We hypothesized that in antiretroviral therapy (ART) chronically suppressed HIV-1+ individuals addition of Peg-IFN-a2b to ART, including of a short ART interruption (to induce HIV reactivation), would decrease rectal tissue HIV levels by triggering anti-HIV mechanisms.
20 ART chronically suppressed (<50 copies/ml) HIV-1+ subjects received 20 weeks of Peg-IFN-a2b. ART was continued for the first 5 weeks, followed by a 4-week interruption, and resumption from week 9-20. Viral load (VL) and CD4+ T cell levels were monitored throughout the treatment. Parameters assessed at baseline (BL) and after 20 weeks of treatment (EoT) included: a) immune activation markers (e.g. CD38, CD69, NKG2A, NKG2C, KIR) and IFN-responsive molecules (e.g. CD169, Tetherin) on cryopreserved peripheral blood mononuclear cells (PBMC) by flow cytometry, b) soluble markers of immune activation (CD14, CRP, D-dimer, IL-6, CD163) in plasma by ELISA, and c) HIV RNA in rectal mucosa biopsies by in situ hybridization (confirmed by reverse transcriptase-ddPCR). Differences between BL and EoT were tested, using non-parametric Wilcoxon Sign-Rank test or paired t-tests, depending on data distribution. A p<0.05 was considered significant.
17/20 subjects completed the treatment; 3 subjects were withdrawn prematurely due to adverse event (AEs; neutropenia). 9/17 subjects had VL>50 copies/ml during ART interruption, returning to undetectable upon ART re-initiation. Coupled (BL-EoT) rectal biopsies were available for 15/17 subjects with 7 of them having detectable tissue in situ HIV RNA at BL. Of these, 7/7 had a decrease in tissue HIV RNA at EoT, with a complete loss of detectable tissue HIV RNA in 5/7. 1 subject had detectable tissue HIV RNA at EoT, but not at BL. We observed a decrease in CD4+ T cell count and an increase in CD4+ and CD8+ T cell activation (CD38, HLA-DR, PD1) and Tetherin expression between BL and EoT. Higher frequencies of CD56bright and lower of CD56dimCD16+ NKs at EoT were also found, as well as an increase in CD38 and NKG2A in both NK subsets. In the myeloid compartment, we noted an increase in CD169 and Tetherin, and in plasma levels of CD163. No changes in plasma CD14, CRP, D-dimer, or IL-6 were found.
20 weeks of combined Peg-IFN-a2b+ART, including a 4-week ART interruption, result in a decrease in tissue HIV RNA and an increase in peripheral innate and adaptive immune activation.